Strides Shasun gets USFDA nod for Cyproheptadine Hydrochloride tablets
Strides Shasun announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (US FDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck &Co. Inc.
According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately $20 million. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.
The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.
The stock is currently trading at Rs642.40, up by Rs0.55 or 0.09% from its previous closing of Rs641.85 on the BSE. The scrip opened at Rs654 and has touched a high and low of Rs654 and Rs632 respectively.